rsv/hmpv/piv3 vaccine
Vaccineexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 17, 2024 (NCT06604767)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Human parainfluenza virus 3Immunity, active
Human parainfluenza virus 3 immunity, active
- Human metapneumovirusImmunity, active
Human metapneumovirus immunity, active
- Respiratory syncytial virusImmunity, active
Respiratory syncytial virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07295028 | Phase 1 | Nov 17, 2025 | Emeritus Research, Veritas Research., Corp., Vicebio |
| NCT06850051 | Phase 1 | Mar 19, 2025 | Sanofi |
| NCT06604767 | Phase 1 | Sep 17, 2024 | Sanofi-Aventis |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Emeritus Research | For profit | 1 | 0 | 1 | 2025 |
| Sanofi | For profit | 1 | 1 | 1 | 2025 |
| Sanofi-Aventis | For profit | 1 | 1 | 1 | 2024 |
| Veritas Research., Corp. | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Vicebio | For profit | 1 | 1 | 1 | 2025 |
5 organizations
Page 1 / 1